Business
MBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant Award
CARMEL, Ind. and BURLINGTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointment of Mark R. Soued, MBA, as Chief Commercial Officer (CCO). Mr. Soued brings more than two decades of commercial leadership across global biopharmaceutical organization
About this update from Alnylam Pharmaceuticals, Inc.
[{"type":"image","alt":"MBX Biosciences, Inc.","displaySize":"","headline":null,"caption":"MBX Biosciences, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":118,"url":"https://media.zenfs.com/en/globenewswire.com/8cd3831a50ba14ff9e3ffa7d6e7ec405"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_C0n7VcB_HB0.oFrvSxAdA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2NQ--/https://media.zenfs.com/en/globenewswire.com/8cd3831a50ba14ff9e3ffa7d6e7ec405","width":300,"height":118}},"lazy":false},{"type":"text","content":"CARMEL, Ind. and BURLINGTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointment of Mark R. Soued, MBA, as Chief Commercial Officer (CCO). Mr. Soued brings more than two decades of commercial leadership across global biopharmaceutical organizations, with deep expertise in product launches, market access, and building high-performing commercial teams.","length":605,"tagName":"p"},{"type":"image","alt":"2026-05-07 -- MBX -- Mark Soued New CCO -- Headshot","displaySize":"","headline":null,"caption":"2026-05-07 -- MBX -- Mark Soued New CCO -- Headshot","className":"","disableSlideshowImg":false,"size":{"original":{"width":1649,"height":1649,"url":"https://media.zenfs.com/en/globenewswire.com/5e23ccf4b3952aff28c87ae1852189e6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/rZeyAPPZj77z_T2xa5Np.Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTk2MA--/https://media.zenfs.com/en/globenewswire.com/5e23ccf4b3952aff28c87ae1852189e6","width":960,"height":960},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/pgeBEiq0JlFkDlxv8S1yUA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0yNDAw/https://media.zenfs.com/en/globenewswire.com/5e23ccf4b3952aff28c87ae1852189e6","width":1200,"height":1200}}},{"type":"text","content":"","length":0,"tagName":"p"},{"type":"text","content":""Mark is an exceptional commercial leader with a demonstrated ability to build and scale commercial organizations and bring products to market," said Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences. "His track record of delivering landmark product launches and generating significant reven...